Please use this identifier to cite or link to this item:
http://dspace.bits-pilani.ac.in:8080/jspui/xmlui/handle/123456789/13528Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Gaikwad, Anil Bhanudas | - |
| dc.date.accessioned | 2023-12-27T06:56:44Z | - |
| dc.date.available | 2023-12-27T06:56:44Z | - |
| dc.date.issued | 2023-11 | - |
| dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0024320523007300 | - |
| dc.identifier.uri | http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13528 | - |
| dc.description.abstract | Targeting Toll-like receptor 4 (TLR4) and Angiotensin II type 1 receptor (AT1R) could provide renoprotection during acute kidney injury (AKI) mainly by regulating inflammation, oxidative stress, mitochondrial dysfunction, and apoptosis. Phloretin (TLR4 inhibitor) as an add-on therapy to losartan (AT1R inhibitor) could provide more therapeutic benefits against AKI under diabetic condition. We aimed to study the effect of phloretin as an add-on therapy to losartan against AKI under diabetic condition. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Elsevier | en_US |
| dc.subject | Pharmacy | en_US |
| dc.subject | Inflammation | en_US |
| dc.subject | Phloretin | en_US |
| dc.subject | Toll-like receptor-4 (TLR4) | en_US |
| dc.subject | Diabetes | en_US |
| dc.subject | Acute Kidney Injury (AKI) | en_US |
| dc.title | Phloretin as an add-on therapy to losartan attenuates diabetes-induced AKI in rats: A potential therapeutic approach targeting TLR4-induced inflammation | en_US |
| dc.type | Article | en_US |
| Appears in Collections: | Department of Pharmacy | |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.